Evofem Announces Voting Results from Special Meeting of Stockholders Evofem Biosciences (OTCID: EVFM) announced on October 20, 2025 that its stockholders did not approve the Amended and Restated Merger Agreement with Aditxt (NASDAQ: ADTX), and Evofem has exercised its rights to terminate the Merger Agreement.The company said it will pivot to regain a national listing for its stock and secure growth capital to catalyze net sales while targeting sustainable positive EBITDA in 2027. Evofem noted a continuing collaboration with Aditxt to commercialize Mitomic diagnostic tests under their September 2024 agreement.Evofem commercializes two FDA-approved sexual health products, PHEXXI vaginal gel and SOLOSEC oral granules, and reported 2024 was its fourth consecutive year of net sales growth.

#EVFM #ADTX Evofem Announces Voting Results from Special Meeting of Stockholders

www.stocktitan.net/news/EVFM/evofem-announc...

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms Evofem Biosciences (OTCID: EVFM) reported significant success from its August 2025 "Say Vagina" campaign, designed to normalize clinical anatomical language. The campaign generated over 2.5 million views across social media platforms and drove a 130% increase in traffic to PHEXXI.com, the company's hormone-free contraceptive product website.Key achievements include PHEXXI becoming the #1 most followed contraceptive brand among healthcare providers, and CEO Saundra Pelletier's Instagram reach growing by 400%. The company plans to launch SayVaginaStore.com in September, with all proceeds from campaign merchandise being donated to selected sexual and reproductive health charities.

#EVFM #ADTX Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

www.stocktitan.net/news/EVFM/evofem-s-say-v...

Majority Support Secured: Evofem-Aditxt Women's Health Merger Heads to Critical September Vote Women's health company Evofem has secured 53.71% voting power support for merger with Aditxt, including Series E-1 and G-1 holders. Special stockholder meeting scheduled for September 26.

#EVFM #ADTX Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

www.stocktitan.net/news/EVFM/evofem-anticip...

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis Evofem Biosciences (OTCID: EVFM) announced that a new U.S. patent for SOLOSEC®, their single-dose oral treatment for bacterial vaginosis and trichomoniasis, has been listed in the FDA Orange Book. The newly listed patent (No. 12,280,037) covers the method, pharmaceutical composition, and use in treating trichomoniasis, extending market exclusivity until December 2041.SOLOSEC is notable as the first and only FDA-approved single-dose oral treatment for both bacterial vaginosis and trichomoniasis. The company is currently conducting a Phase 4 clinical trial comparing SOLOSEC's effectiveness and cost-effectiveness against metronidazole in treating T. vaginalis infections, which affect an estimated 6.9 million new cases annually in the U.S.

#EVFM #ADTX FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

www.stocktitan.net/news/EVFM/fda-orange-boo...

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update Evofem Biosciences (OTCID: EVFM) reported improved financial results for Q2 2025, with net sales increasing 16% to $4.8 million compared to $4.2 million in Q2 2024. The company reduced its loss from operations to $1.3 million from $1.4 million year-over-year.Key developments include advancing strategies to reduce manufacturing costs by 50% for PHEXXI and SOLOSEC, expanding into UAE markets, and progress in clinical trials. The company is proceeding with plans to become a wholly-owned subsidiary of Aditxt, having raised $2.4 million through senior subordinated notes and warrants in Q2 2025.The company reported a net loss of $(0.02) per share compared to a net income of $0.02 per share in Q2 2024, with cash and equivalents of $0.7 million as of June 30, 2025.

#EVFM #ADTX Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

www.stocktitan.net/news/EVFM/evofem-reports...

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy Evofem Biosciences (NASDAQ:EVFM) has achieved significant social media success with its non-hormonal birth control brand PHEXXI through a viral TikTok campaign focused on microfeminism. The campaign, which generated over 10 million views and 24,000+ comments, sparked widespread media coverage from major outlets including BuzzFeed, MSN, and Scary Mommy.The campaign's success aligns with PHEXXI's brand positioning as a hormone-free birth control option that emphasizes women's choice and autonomy. CEO Saundra Pelletier highlighted the brand's commitment to challenging norms in women's health, with plans for continued bold marketing initiatives in August.

#EVFM #ADTX Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

www.stocktitan.net/news/EVFM/phexxi-a-non-h...

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting Evofem Biosciences (OTCPK: EVFM) presented promising study results for SOLOSEC (secnidazole) in treating recurrent bacterial vaginosis (BV) at the 2025 ACOG Annual Meeting. The clinical study of 24 women showed that once-weekly dosing of SOLOSEC 2g oral granules demonstrated efficacy comparable or potentially superior to current CDC-recommended suppressive treatments. BV affects approximately 21 million U.S. women, with up to 50% experiencing recurrence within six months of treatment. The BV treatment market is projected to reach $1.0 billion in the U.S. by 2033. While SOLOSEC is currently approved for BV treatment in women aged 12 and older, its use in recurrent BV remains investigational. The simplified once-weekly oral dosing regimen could potentially improve treatment adherence compared to more complex existing protocols.

#EVFM #ADTX Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

www.stocktitan.net/news/EVFM/notable-data-o...

Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics Evofem Biosciences (OTCQB: EVFM) has entered into a License and Supply Agreement with Windtree Therapeutics (NasdaqCM: WINT) to reduce manufacturing costs of PHEXXI, their FDA-approved hormone-free contraceptive vaginal gel. The partnership is expected to decrease PHEXXI's manufacturing costs by 55% to 60% from current levels, with no tech transfer costs to Evofem.PHEXXI, which prevents pregnancy by maintaining normal vaginal pH levels inhospitable to sperm, will benefit from Windtree's manufacturing contacts to achieve lower production costs. This cost reduction aims to facilitate PHEXXI's global expansion into price-sensitive markets where non-hormonal contraceptives are in demand.Evofem maintains ownership and continues U.S. commercialization through its sales team, while pursuing international expansion through strategic partnerships, including a July 2024 license agreement with Pharma 1 Drug Store for UAE market entry.

#EVFM #WINT Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics

www.stocktitan.net/news/EVFM/evofem-expects...

Evofem Posts Record 4th Year Growth: Revenue Up 6% as Operating Costs Plunge 27% Evofem's PHEXXI drives 6% sales growth while slashing operating costs by 27%. Company improves operational efficiency with best-ever marketing ratio. See full financial analysis.

#EVFM #ADTX #WINT Evofem Reports Fourth Consecutive Year of Net Sales Growth

www.stocktitan.net/news/EVFM/evofem-reports...

#EVFM #ADTX Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

www.stocktitan.net/news/EVFM/evofem-bioscie...

JUST IN: ( OTC: #EVFM ) InvestorNewsBreaks - Aditxt (NASDAQ: ADTX), Evofem Announce Completion of Third Parent Equity Investment Under Amended Merger Agreement

#StockMarket #News

JUST IN: ( OTC: #EVFM ) Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem

#StockMarket #News